MR studies indicated that the use of lipid-lowering drugs (PCSK9 inhibitors) was associated with an increased risk of AD [34], whereas the overall use of antihypertensive medications and reduction in SBP through variants in genes encoding targets of calcium channel blockers were associated with a lower risk of AD [35]. The gene discussed is PCSK9; the disease is Alzheimer disease.